
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Sales reached $7.08 billion, beating the consensus of $6.94 billion.